Compare AERO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERO | ARQT |
|---|---|---|
| Founded | 1934 | 2016 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | AERO | ARQT |
|---|---|---|
| Price | $19.41 | $26.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $30.83 | $25.00 |
| AVG Volume (30 Days) | 331.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $196,542,000.00 |
| Revenue This Year | $7.14 | $86.38 |
| Revenue Next Year | $4.82 | $30.29 |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | N/A | ★ 229.74 |
| 52 Week Low | $16.00 | $11.86 |
| 52 Week High | $23.05 | $31.77 |
| Indicator | AERO | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 49.04 |
| Support Level | $18.91 | $24.81 |
| Resistance Level | $19.66 | $27.26 |
| Average True Range (ATR) | 1.12 | 1.19 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 39.09 | 50.31 |
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.